WO2012165854A3 - 표적 유전자 발현 억제 및 면역 반응을 동시에 유발하는 이중가닥의 긴 간섭 ｒｎａ - Google Patents

표적 유전자 발현 억제 및 면역 반응을 동시에 유발하는 이중가닥의 긴 간섭 ｒｎａ Download PDF

Info

Publication number
WO2012165854A3
WO2012165854A3 PCT/KR2012/004259 KR2012004259W WO2012165854A3 WO 2012165854 A3 WO2012165854 A3 WO 2012165854A3 KR 2012004259 W KR2012004259 W KR 2012004259W WO 2012165854 A3 WO2012165854 A3 WO 2012165854A3
Authority
WO
WIPO (PCT)
Prior art keywords
expression
target genes
immune reaction
inhibition
interfering dsrna
Prior art date
Application number
PCT/KR2012/004259
Other languages
English (en)
French (fr)
Other versions
WO2012165854A9 (ko
WO2012165854A2 (ko
Inventor
이동기
장찬일
Original Assignee
성균관대학교산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 성균관대학교산학협력단 filed Critical 성균관대학교산학협력단
Priority to US14/123,056 priority Critical patent/US20140249304A1/en
Publication of WO2012165854A2 publication Critical patent/WO2012165854A2/ko
Publication of WO2012165854A3 publication Critical patent/WO2012165854A3/ko
Publication of WO2012165854A9 publication Critical patent/WO2012165854A9/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

본 발명은 RNAi-매개 특정 표적 유전자 발현을 억제할 뿐만 아니라 면역 반응을 촉진할 수 있는 이중가닥의 긴 간섭 RNA 구조(long interfering dsRNA, liRNA) 및 그 용도에 관한 것으로, 보다 상세하게는, 서열 특이적으로 RNA 간섭 반응을 통해 특정 표적 유전자의 발현을 억제시킬 뿐만 아니라, 구조 의존적으로 단백질 키나아제 R (PKR) 경로를 자극시켜 인터페론 β의 발현을 유도할 수 있는 이중가닥의 긴 간섭 RNA 구조에 관한 것이다.
PCT/KR2012/004259 2011-05-30 2012-05-30 표적 유전자 발현 억제 및 면역 반응을 동시에 유발하는 이중가닥의 긴 간섭 ｒｎａ WO2012165854A2 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/123,056 US20140249304A1 (en) 2011-05-30 2012-05-30 Long interfering dsrna simultaneously inducing an immune reaction and the inhibition of the expression of target genes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110051641A KR101590586B1 (ko) 2011-05-30 2011-05-30 표적 유전자 발현 억제 및 면역 반응을 동시에 유발하는 이중가닥의 긴 간섭 ｒｎａ
KR10-2011-0051641 2011-05-30

Publications (3)

Publication Number Publication Date
WO2012165854A2 WO2012165854A2 (ko) 2012-12-06
WO2012165854A3 true WO2012165854A3 (ko) 2013-03-28
WO2012165854A9 WO2012165854A9 (ko) 2013-05-23

Family

ID=47260072

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/004259 WO2012165854A2 (ko) 2011-05-30 2012-05-30 표적 유전자 발현 억제 및 면역 반응을 동시에 유발하는 이중가닥의 긴 간섭 ｒｎａ

Country Status (3)

Country Link
US (1) US20140249304A1 (ko)
KR (1) KR101590586B1 (ko)
WO (1) WO2012165854A2 (ko)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2395085B1 (en) * 2009-02-04 2015-06-10 Sungkyunkwan University Foundation for Corporate Collaboration Small interference rna complex with increased intracellular transmission capacity
CA2818662C (en) 2010-10-22 2021-07-06 Sungkyunkwan University Foundation For Corporate Collaboration Nucleic acid molecule inducing rna interference, and uses thereof
EP3514236A1 (en) 2012-05-22 2019-07-24 Olix Pharmaceuticals, Inc. Rna-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor
SK500652015A3 (sk) * 2015-10-15 2017-05-03 Ústav Polymérov Sav Spôsob úpravy funkčného stavu ľubovoľnej mRNA umožňujúci jej selektívne a špecifické rozpoznanie
JP7027311B2 (ja) 2015-11-16 2022-03-01 オリックス ファーマシューティカルズ，インコーポレーテッド ＭｙＤ８８又はＴＬＲ３を標的とするＲＮＡ複合体を使用した加齢黄斑変性の治療
CA3022877A1 (en) 2016-02-02 2017-08-10 Olix Pharmaceuticals, Inc. Treatment of angiogenesis-associated diseases using rna complexes that target angpt2 and pdgfb
WO2017134525A1 (en) 2016-02-02 2017-08-10 Olix Pharmaceuticals, Inc. TREATMENT OF ATOPIC DERMATITIS AND ASTHMA USING RNA COMPLEXES THAT TARGET lL4Rα, TRPA1, OR F2RL1
US10301628B2 (en) 2016-04-11 2019-05-28 Olix Pharmaceuticals, Inc. Treatment of idiopathic pulmonary fibrosis using RNA complexes that target connective tissue growth factor
KR101916652B1 (ko) 2016-06-29 2018-11-08 올릭스 주식회사 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도
CN110770343A (zh) * 2017-02-10 2020-02-07 成均馆大学校产学协力团 用于rna干扰的长双链rna
US20230095192A1 (en) * 2020-03-03 2023-03-30 University Of Washington Synthetic agonists of dna-pk and their use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011505868A (ja) * 2007-12-18 2011-03-03 ドンギ イ オフターゲット効果を極力抑えるとともに、ＲＮＡｉ機構を飽和させない新規なｓｉＲＮＡ構造及びその用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080249040A1 (en) * 2001-05-18 2008-10-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of sterol regulatory element binding protein 1 (SREBP1) gene expression using short interfering nucleic acid (siNA)
JP5244087B2 (ja) * 2006-03-23 2013-07-24 サンタリス ファーマ アー／エス 低分子内部セグメント化干渉ｒｎａ
WO2009008645A2 (en) * 2007-07-06 2009-01-15 Mogam Biotechnology Research Institute Linear double-stranded rna molecule interfering with different target genes
KR101141544B1 (ko) * 2009-03-13 2012-05-03 한국과학기술원 에스아이알엔에이 다중 접합체 및 이의 제조방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011505868A (ja) * 2007-12-18 2011-03-03 ドンギ イ オフターゲット効果を極力抑えるとともに、ＲＮＡｉ機構を飽和させない新規なｓｉＲＮＡ構造及びその用途

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"pSUPER RNAi System; A Vector System for Expression of Short Interfering RNA", CATALOG # VEC-PRT-0002, 1 May 2003 (2003-05-01) *
BRID M. RYAN. ET AL.: "Survivin: A new target for anti-cancer therapy", CANCER TREATMENT REVIEWS, vol. 35, 2009, pages 553 - 562 *
CAROL A. SLEDZ. ET AL.: "Activation of the interferon system by short interfering RNAs", NATURE CELL BIOLOGY, vol. 5, 2003, pages 834 - 839 *
CHAN LL CHANG. ET AL.: "Asymmetric Shorter duplex siRNA Structures Trigger Efficient Gene Silencing With Reduced Nonspecific Effects", MOL THER., vol. 17, 2009, pages 725 - 732 *
CHAN LL CHANG. ET AL.: "Dual Target Gene Silencing by Using Long, Synthetic siRNA Duplexes without Triggering Antiviral Responses", MOL. CELLS, vol. 27, 2009, pages 689 - 695 *
SAYDA M. ELBASHIR. ET AL.: "RNA interference is mediated by 21- and 22-nucleotide RNAs", GENES DEV., vol. 15, 2001, pages 188 - 200 *

Also Published As

Publication number Publication date
WO2012165854A9 (ko) 2013-05-23
WO2012165854A2 (ko) 2012-12-06
KR20120133127A (ko) 2012-12-10
US20140249304A1 (en) 2014-09-04
KR101590586B1 (ko) 2016-02-01

Similar Documents

Publication Publication Date Title
WO2012165854A3 (ko) 표적 유전자 발현 억제 및 면역 반응을 동시에 유발하는 이중가닥의 긴 간섭 ｒｎａ
MX2018013216A (es) Composiciones y metodos para inhibir la expresion del gen de proteasa transmembrana, serina 6 (tmprss6).
MX2019012252A (es) Composiciones y metodos para inhibir la expresion del gen alas1.
WO2013014294A3 (en) Improved baculovirus expression systems
MX2021015290A (es) Composiciones y metodos para inhibicion de genes para apolipoproteina c-iii (apoc3).
MX2014003979A (es) Nucleosidos, nucleotidos, y acidos nucleicos modificados, y usos de los mismos.
MX2021010716A (es) Composiciones y metodos para inhibir la expresion del gen lect2.
WO2012006241A3 (en) Methods and compositions for the specific inhibition of androgen receptor by double-stranded rna
WO2015003113A3 (en) Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded rna
MX355356B (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
WO2012006243A3 (en) Methods and compositions for the specific inhibition of beta-catenin by double-stranded rna
MX2014004539A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
MX2022001017A (es) Composiciones y metodos para inhibir la expresion del gen de sintasa de acido 5'-aminolevulinico 1 (alas1).
MX2019011805A (es) Plantas de melon con resistencia al virus asociado al amarilleamiento del melon (myav).
MY160677A (en) Fermented infant formula
WO2016183009A3 (en) Methods and compositions for the specific inhibition of antithrombin 3 (at3) by double-stranded rna
WO2012177921A3 (en) Compositions and methods for inhibiting hepcidin antimicrobial peptide (hamp) or hamp-related gene expression
WO2014093746A3 (en) Methods and compositions for the specific inhibition of ckap5 by double-stranded rna
WO2012145582A3 (en) Methods and compositions for the specific inhibitions of egfr by double-stranded rna
WO2013053857A3 (en) Gene cluster for biosynthesis of griselimycin and methylgriselimycin
WO2013063528A3 (en) Isoprene synthase variants with improved solubility for production of isoprene
WO2012106702A3 (en) Treatment of leukemia
WO2013030654A8 (en) Processes for the preparation of (r)-2-acetamido-n-benzyl-3-methoxypropionamide and intermediates thereof
WO2012141989A3 (en) Immunogens
UA92645U (en) 5-[(4-chloro-1h-imidazol-5-yl)methylene]-2-thioxo-1,3- thiazolidin-4-ones exhibiting hypoglycemic activity

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12793378

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 14123056

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 12793378

Country of ref document: EP

Kind code of ref document: A2